Search Results
Showing Results for microsatellite instability
Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise ...
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
Oesophageal cancer is the eighth most commonly diagnosed cancer and is the sixth leading cause of cancer death worldwide.1,2Â Worldwide, around 604,100 new instances of oesophageal cancer were recorded in 2020, leading to approximately 544,100 deaths. This translates to a standardized incidence rate ...
Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1Â Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2Â ...
The ESMO GI 2024 meeting, held this year in Munich, Germany, brought together researchers and clinicians from around the world to discuss recent developments in gastrointestinal malignancies.
The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1Â Platinum-based chemotherapy had long been the standard of care in ...
To further understand the key developments and research presented in the field of gynaecological oncology at ESMO 2023, we spoke with Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology at the Fondazione Policlinico Universitario Agostino Gemelli - UCSC Italy. In our ...
The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. ...
touchONCOLOGY spoke with editorial board member Ben Weinberg (Georgetown University, Washington, DC, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. This includes data from the Plenary Session randomized phase 3 noninferiority PROSPECT trial, ...
Oesophageal cancer (OC) is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide,1 with approximately 604,000 new cases in 2020.2 OC has two main histological subtypes: oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC). Worldwide, ...
Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree and are classified into cholangiocarcinoma (CCA) and gallbladder cancer. BTC is an aggressive and rare epithelial malignancy that is usually ...
Cancers of the oesophagus and oesophagogastric junction (OGJ), termed upper gastrointestinal (UGI) cancers, are lethal and constitute a significant public health problem. In 2020, 604,000 cases and 544,000 UGI cancer-related deaths were estimated worldwide.1Â UGI cancers are the seventh most frequently diagnosed cancer ...
Until recently, treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor receptor (EGFR) monoclonal antibody, namely cetuximab and panitumumab, or an anti-angiogenic agent such as bevacizumab, aflibercept or ramucirumab. ...
Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase ...
Gastro-oesophageal cancers (GEC), which include both gastric (GC) and oesophageal cancers (EC), are among the most common cancers globally.1Â In the USA, the American Cancer Society estimated 20,640 new diagnoses of EC and 26,380 new diagnoses of GC, each contributing to 16,410 and 11,090 ...
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. While they account for around 3% of all gastrointestinal malignancies, they are the second most common primary liver cancer.1Â CCAs tend to metastasize and have early lymph node ...
Sarcomas are a diverse group of rare muscle, bone and connective tissue tumours. Within soft-tissue sarcoma alone, there are over 70 subtypes, which demonstrate substantial heterogeneity in biology, genetics and clinical behaviour.1Â Further complicating their management is the range of treatment ...
Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that were presented at the ASCO Gastrointestinal Cancers Symposium 2022. GALAXY study in CIRCULATE-Japan abstract: https://ascopubs.org/doi/...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
